Prostate cancer
NEW --- Sequencing treatments in mCRPC patients without HRR gene mutations
Educational Objective: Gain insight in the current treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) patients without homologous recombination repair (HRR) gene mutations.
Specialty: Medical oncology, Clinical oncology, Urology
Target Audience: Specialists (CME: basic, intermediate, advanced), Residents (senior)
Latest update: July 2024
Background:
The optimal choice and sequence of life-prolonging treatments for an individual patient with mCRPC is challenging. This topic is limited to patients with a castrate serum testosterone level (<50 ng/dl or 1.7 nmol/l). Bone-protective agents fall beyond the scope of this topic.
Regulatory approval status of drugs for mCRPC discussed in this topic (indications limited to the mCRPC setting, status 26 July 2024)
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please check your local prescribing information.